Black hairy tongue during interferon therapy for hepatitis C

A 64-year-old woman with history of chronic hepatitis related to Hepatitis C virus [(HCV), genotype 1b] infection received treatment with pegylated interferon (PEG-IFNα2a) and rivabirin noticed a black coloration of her tongue during the thirtythird week of treatment (Figure 1). She had no other relevant past medical history and was a nonsmoker. She did not refer any pain, discomfort or other symptoms in the oral cavity. Physical examination showed a black hyperpigmentation and elongation of the phylliform papillae on the dorsal surface of the tongue. After appropriate diagnosis and counseling, pigmentation attenuated and later disappeared allowing completion of therapy. Black hairy tongue (BHT), also called lingua villosa nigra, is a benign disorder characterized by hypertrophied and elongated phylliform papillae on the surface of the tongue, caused by defective desquamation.1,2 Its clinical expression is an abnormal black coating of the dorsal surface of the tongue, usually in the posterior third. Associated involvement of the skin and oral mucosa has been described.3 Hyperpigmentation is usually asymptomatic, although symptoms such as altered taste, nausea, and halitosis have been reported.4,5 The prevalence of BHT in general population is variable, with higher rates described in oral medicine patients.1 Tobacco use is the more frequent aggravating or causative factor. Excessive alcohol intake, xerostomia, poor oral hygiene, oxidizing mouthwashes, and a number of drugs have been also associated to this disorder. Among medications antibiotics, antipsychotics, proton pump inhibitors, immunosupresors, antifungals and oral contraceptives are mentioned in different reports. They most likely share the potential to cause xerostomia.1 Many types of adverse skin reactions, mainly of a lichenoid type, have been described during therapy with PEG-IFN for chronic HCV infection, with a synergistic effect of combination therapy with ribavirin. Eczema, erythema and rash are common.6 BHT has been reported as a rare adverse reaction of PEG-IFN therapy for HCV, with nearly 20 cases described in literature. Reported cases include predominantly dark-skinned patients,3,4,6-8 with few reports on Caucasian patients.9-11 The temporal relationship between the onset of the treatment and the appearance of the pigments spots range from 1 to 10 months.3 It appears not to be related to age, gender, HCV genotype, and doses of PEG-IFN or ribavirin, duration of treatment or treatment outcome.3 Although the exact mechanism underlying oral hyperpigmentation in patients treated with PEG-IFN and ribavirin is still unknown, it

Abstract licence: CC BY-NC-ND

13 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.